Jamieson announces nationwide distribution of breakthrough psoriasis remedy Dermylex(TM)

Unique product developed by Canadian company Advitech (TSX-V:AVI)

TORONTO, Ontario – Jamieson Laboratories, Canada’s leading manufacturer of
natural health products, today announced that Dermylex™, a clinically-proven psoriasis
remedy, is now available at leading pharmacies and retailers across Canada.
Developed by leading Canadian health sciences and technology firm Advitech Inc. (TSXV:
AVI) and exclusively distributed by Jamieson, Dermylex is a patented blend of
bioactive peptides from a natural source, with properties that have been rigorously
demonstrated through scientific studies. It acts as an immune system regulator in autoimmune
diseases such as psoriasis. During clinical trials, patients who responded to
Dermylex generally began to see an improvement within 56 days.

Dermylex is not a topical treatment, but a tablet taken orally. This makes treatment more
convenient. It is also a product of natural origin. Its effectiveness has been demonstrated
using the same rigorous parameters as is used for pharmaceuticals, but it features the
safety profile of natural health products.

Former Canadian Olympian Pierre Harvey, who is amongst an estimated one million
Canadians who suffer from psoriasis, is a user. “Suffering from mild to moderate
psoriasis for many years, I heard about Dermylex and decided to try it to see for myself
its effect on this disease,” said Mr. Harvey. “Very rapidly, my psoriasis has improved
after taking Dermylex, a natural health product clinically proven and scientifically
supported to relieve psoriasis symptoms. I agreed to promote the product because of my
personal confidence in the product and its proven effectiveness, in my case. Dermylex
simply works very well.”

“This product is ideal for consumers suffering from mild to moderate psoriasis,” explains
Tracey Mazza, Brand Manager, Jamieson Laboratories. “It’s an affordable, effective and
safe solution and we are pleased that is now widely available across the country through
our many pharmacy and retail partners.”
A recently completed randomized, double-blind, placebo-controlled, clinical trial of
Dermylex by Advitech has demonstrated the nutritional supplement’s measurable impact
on relieving psoriasis symptoms. This study supports the results obtained in a previously
conducted open label study also conducted on Dermylex.

At the conclusion, some 56 days later, patients taking Dermylex saw a reduction of their
scaly plaques and itching compared to a placebo. Furthermore, the improvement was
maintained over a period of at least 56 additional days at the same dosage. 1, 2
Psoriasis is a non-contagious chronic skin disease, characterized by patches of red,
inflamed skin that are covered with a flaky, silvery scaling. These patches, or lesions,
generally appear on the scalp, elbows, hands, knees, lower back, and buttocks and can
often be itchy and painful. Psoriasis is caused by an immune system disorder that affects
skin cell activity. Dermylex retails for $59.99 for 60 tablets. For more information please
visit www.dermylex.ca.


About Jamieson Laboratories
Established in 1922, Jamieson Laboratories is Canada’s largest manufacturer and
distributor of advanced natural health care products. Jamieson’s state-of-the-art
pharmaceutical manufacturing laboratories are located in Windsor, Ontario. The
company is a world leader in the vitamin and nutrition industry, exporting to over 45
countries including the United States, China, Japan, Hong Kong, Korea and Singapore.
For more information, please visit the Jamieson Laboratories website at
www.jamiesonlabs.com or call 1 800 265-5088.

About Advitech
Advitech is a health sciences and technology company with a mission to discover and
commercialize proprietary and evidence-based natural health products. Effective and
safe, these products play a role in the prevention of Immune-Mediated Inflammatory
Disorders (IMID), such as psoriasis and inflammatory bowel disease. Advitech's common
shares are listed on the TSX Venture Exchange under the symbol AVI. The number of
common shares outstanding is 61,247,318.

For further information, please contact:
John B. Challinor II APR Stephanie Blok
Director of Communications Manager of Public Relations
Jamieson Laboratories Jamieson Laboratories
(416) 960-0052, Ext. 4205 (416) 960-0052, Ext. 2714
[email protected] [email protected]

1Clinical study-1: Open label: Poulin Y, Pouliot Y, Lamiot E, Aattouri N, Gauthier SF, Safety and efficacy
of a milk-derived extract in the treatment of plaque psoriasis: An open-label study, J Cutan Med Surg. 2005
Dec .
2Clinical study -2: Double-blind against placebo: Poulin Y, Bissonnette R, Juneau C, Cantin K, Drouin R,
Poubelle PE. XP-828L in the treatment of mild-to-moderate psoriasis: A randomized, double blind placebocontrolled
study. J Cutan Med Surg. (in press).

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.